

***Blastoactiva* is the first skin cell repair cream with double A select centella asiatica**

Almirall enhances its dermatology area with a new dermopharmaceutical product to activate, repair and renew aggravated skin

Barcelona, 22 September 2009.- This autumn a new product from Almirall's dermatology area will be launched onto the pharmaceutical market: *Blastoactiva*. ***Blastoactiva*** is the first skin cell repair cream with double A select centella asiatica to **activate, repair and renew aggravated skin**. The dermopharmaceutical product's exclusive formula comes from centella asiatica cultivated in Madagascar under strict scientific controls to ensure a high concentration of the purest and most effective active ingredients. A rigorous extraction process obtains two active ingredients selected from the centella asiatica: **asiatic acid and asiaticoside**, giving rise to the name *double A select*.

Blastoactiva revitalises cells and stimulates renewal of the epidermis from the inside. It is particularly indicated for two therapeutic areas: **skin affected by various factors** such as surface aggressions in post-scarring phase, irritations from cold weather, dryness, wind or pollution, surface acne scars and solar erythemas, and secondly, **aggravated skin after certain kinds of cosmetic treatments** such as laser treatment, peelings, hair removal, shaving, tattoos or post UVA treatment. Due to its broad range of indications this cosmetic product can be used throughout the whole year.

Blastoactiva cream has been tested dermatologically and is well-tolerated by the skin and well-accepted by users.

With this new launch, Almirall further increases its range of skin products. It already has another solution on the market for the care of damaged skin, ***Blastoestimulina***, which is an **anti-bacterial cicatrising and regenerating cream** also with a centella asiatica base.

Blastoactiva will be presented in Spain during the National Dermopharmacy Meeting to be held in Palma de Mallorca this September.

About Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.

Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 11 affiliates.

For further information please visit the website at: www.almirall.com/ www.blastoactiva.es

More information:

HCBCN

Cristina Castro / Maria Fernández

932 52 52 52

c.castro@hc-bcn.com